Business Context and Reporting Period
This Form 8-K was filed by Recursion Pharmaceuticals, Inc. on July 13, 2021. The report discloses the formation of a new Therapeutics Advisory Board, chaired by Joseph Miletich, MD, PhD, as detailed in a press release issued on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a corporate governance event and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the establishment of the Therapeutics Advisory Board. No financial or operational changes compared to a prior period are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. It includes a standard Regulation FD disclosure stating that the press release information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the full composition and expertise of the newly formed Therapeutics Advisory Board.
- Review the attached Exhibit 99.1 (Press Release) for specific details on the board's mandate.
- Consult the company's most recent 10-Q or 10-K for actual financial performance data, as this 8-K contains none.